Millions of individuals taking widely prescribed blood pressure medications may face a heightened risk of developing serious kidney complications, particularly those with type 2 diabetes, according to new research. A study presented at the European Renal Association Congress in Glasgow suggests that patients using dihydropyridine calcium-channel blockers (DCCBs), a common class of drugs that includes amlodipine and lacidipine, experienced a 33 percent greater risk of kidney issues compared to those on other antihypertensive medications.
DCCBs function by widening and relaxing blood vessels, which lowers blood pressure and can reduce the risk of heart attack and stroke. In the UK, these medications are frequently prescribed to the approximately 16 million people living with high blood pressure. Amlodipine alone accounts for about 41 million prescriptions annually, with other common examples including felodipine, lercanidipine hydrochloride, nicardipine hydrochloride, nifedipine, and nimodipine.
Study Details and Findings
The recent study focused on over 31,000 adults with type 2 diabetes, a condition that itself elevates the risk of kidney problems due to the strain excess blood sugar places on the kidneys' filtering systems. Over a five-year period, researchers observed that roughly 40 percent of these participants were taking DCCBs. All individuals in the study were also receiving other treatments aimed at preventing kidney damage, a standard practice for diabetic patients.
The findings revealed that participants on DCCBs faced a 33 percent increased likelihood of experiencing significant kidney problems. This included a decline of over 40 percent in kidney function, which measures how effectively the kidneys filter waste from the blood. Furthermore, these patients were more prone to developing end-stage kidney disease, a severe condition requiring dialysis or a transplant, commonly known as kidney failure.
Expert Concerns and Potential Mechanisms
Dr. Timna Agur, a senior nephrologist at Rabin Medical Center and lead author of the study, stated that the results necessitate critical evaluation of whether DCCBs are consistently the optimal choice for patients already undergoing kidney-protective treatments. Researchers hypothesize that DCCBs might disrupt blood flow within the kidneys, potentially by over-relaxing blood vessels and causing excess fluid to overwhelm the kidney's filtration system, thereby contributing to further damage.
While the researchers emphasized that their study could not definitively establish causation, they underscored the importance of their findings and the need for additional investigation. Dr. Agur noted that given the widespread use of these medications, any identified increase in kidney risk carries substantial implications for a large patient population.
Broader Context of Kidney Disease
These findings emerge amidst ongoing calls for improved early detection of diabetes-related kidney disease. The condition affects over seven million Britons, yet an estimated 30 to 50 percent of cases go undiagnosed. Research from Kidney Care UK indicates that a significant majority of individuals with diabetes and high blood pressure who develop kidney disease were not informed about their elevated risk. Moreover, nearly 40 percent of people with diabetes are reportedly missing simple urine tests that could identify early signs of kidney damage, hindering timely treatment that could slow or halt disease progression.
Health advocates have urged governments to prioritize resources for early diagnosis and preventative care for at-risk patients, warning of widespread consequences for both individuals and economies if action is not taken.